Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone

X. Mariette; C. Bingham; G. Burmester; V. Bykerk; P. Emery; D. E. Furst; D. Van Der Heijde; R. Van Vollenhoven; B. Vanlunen; C. Arendt; M. Weinblatt

doi:10.1016/S1169-8330(16)30494-X

Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone

X. Mariette, C. Bingham, G. Burmester, V. Bykerk, P. Emery, D. E. Furst, D. Van Der Heijde, R. Van Vollenhoven, B. Vanlunen, C. Arendt, M. Weinblatt

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	A201-A202
Journal	Revue du Rhumatisme (Edition Francaise)
Volume	83
DOIs	https://doi.org/10.1016/S1169-8330(16)30494-X
State	Published - Nov 1 2016

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1016/S1169-8330(16)30494-X

Cite this

Mariette, X., Bingham, C., Burmester, G., Bykerk, V., Emery, P., Furst, D. E., Van Der Heijde, D., Van Vollenhoven, R., Vanlunen, B., Arendt, C., & Weinblatt, M. (2016). Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone. Revue du Rhumatisme (Edition Francaise), 83, A201-A202. https://doi.org/10.1016/S1169-8330(16)30494-X

Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone. / Mariette, X.; Bingham, C.; Burmester, G. et al.
In: Revue du Rhumatisme (Edition Francaise), Vol. 83, 01.11.2016, p. A201-A202.

Research output: Contribution to journal › Article › peer-review

Mariette, X, Bingham, C, Burmester, G, Bykerk, V, Emery, P, Furst, DE, Van Der Heijde, D, Van Vollenhoven, R, Vanlunen, B, Arendt, C & Weinblatt, M 2016, 'Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone', Revue du Rhumatisme (Edition Francaise), vol. 83, pp. A201-A202. https://doi.org/10.1016/S1169-8330(16)30494-X

Mariette X, Bingham C, Burmester G, Bykerk V, Emery P, Furst DE et al. Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone. Revue du Rhumatisme (Edition Francaise). 2016 Nov 1;83:A201-A202. doi: 10.1016/S1169-8330(16)30494-X

@article{1796060762744bfda7eb44b263a8b0ca,

title = "Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone",

author = "X. Mariette and C. Bingham and G. Burmester and V. Bykerk and P. Emery and Furst, {D. E.} and {Van Der Heijde}, D. and {Van Vollenhoven}, R. and B. Vanlunen and C. Arendt and M. Weinblatt",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/S1169-8330(16)30494-X",

language = "English (US)",

volume = "83",

pages = "A201--A202",

journal = "Revue du Rhumatisme (Edition Francaise)",

issn = "1169-8330",

publisher = "Elsevier Masson s.r.l.",

}

TY - JOUR

T1 - Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone

AU - Mariette, X.

AU - Bingham, C.

AU - Burmester, G.

AU - Bykerk, V.

AU - Emery, P.

AU - Furst, D. E.

AU - Van Der Heijde, D.

AU - Van Vollenhoven, R.

AU - Vanlunen, B.

AU - Arendt, C.

AU - Weinblatt, M.

PY - 2016/11/1

Y1 - 2016/11/1

UR - http://www.scopus.com/inward/record.url?scp=85007610487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007610487&partnerID=8YFLogxK

U2 - 10.1016/S1169-8330(16)30494-X

DO - 10.1016/S1169-8330(16)30494-X

M3 - Article

AN - SCOPUS:85007610487

SN - 1169-8330

VL - 83

SP - A201-A202

JO - Revue du Rhumatisme (Edition Francaise)

JF - Revue du Rhumatisme (Edition Francaise)

ER -

Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this